These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 21898375)

  • 1. Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma.
    Molina AM; Feldman DR; Voss MH; Ginsberg MS; Baum MS; Brocks DR; Fischer PM; Trinos MJ; Patil S; Motzer RJ
    Cancer; 2012 Apr; 118(7):1868-76. PubMed ID: 21898375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.
    Kanesvaran R; Watt K; Turnbull JD; Armstrong AJ; Wolkowiez MC; George DJ
    Clin Genitourin Cancer; 2015 Aug; 13(4):319-327. PubMed ID: 26174223
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma.
    Li J; Kluger H; Devine L; Lee JJ; Kelly WK; Rink L; Saif MW
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1193-200. PubMed ID: 27103123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.
    Bitting RL; Healy P; Creel PA; Turnbull J; Morris K; Wood SY; Hurwitz HI; Starr MD; Nixon AB; Armstrong AJ; George DJ
    Clin Genitourin Cancer; 2014 Aug; 12(4):241-50. PubMed ID: 24685058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes GR; Ginsberg MS; Baum MS; Harmon CS; Kim ST; Chen I; Redman BG
    Am J Clin Oncol; 2010 Dec; 33(6):614-8. PubMed ID: 20142724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma.
    Feldman DR; Baum MS; Ginsberg MS; Hassoun H; Flombaum CD; Velasco S; Fischer P; Ronnen E; Ishill N; Patil S; Motzer RJ
    J Clin Oncol; 2009 Mar; 27(9):1432-9. PubMed ID: 19224847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 dose-escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma.
    Rini BI; Stein M; Shannon P; Eddy S; Tyler A; Stephenson JJ; Catlett L; Huang B; Healey D; Gordon M
    Cancer; 2011 Feb; 117(4):758-67. PubMed ID: 20922784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma.
    Sheng X; Yan X; Chi Z; Cui C; Si L; Tang B; Li S; Mao L; Lian B; Wang X; Bai X; Zhou L; Kong Y; Dai J; Ding L; Mao L; Guo J
    EBioMedicine; 2020 May; 55():102755. PubMed ID: 32335374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).
    Molina AM; Hutson TE; Larkin J; Gold AM; Wood K; Carter D; Motzer R; Michaelson MD
    Cancer Chemother Pharmacol; 2014 Jan; 73(1):181-9. PubMed ID: 24190702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
    Dos Santos C; Tijeras-Raballand A; Serova M; Sebbagh S; Slimane K; Faivre S; de Gramont A; Raymond E
    Br J Cancer; 2015 Jan; 112(1):86-94. PubMed ID: 25422908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G; Buonerba C; Federico P; Rescigno P; Milella M; Ortega C; Aieta M; D'Aniello C; Longo N; Felici A; Ruggeri EM; Palmieri G; Imbimbo C; Aglietta M; De Placido S; Mirone V
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells.
    D'Amato C; Rosa R; Marciano R; D'Amato V; Formisano L; Nappi L; Raimondo L; Di Mauro C; Servetto A; Fulciniti F; Cipolletta A; Bianco C; Ciardiello F; Veneziani BM; De Placido S; Bianco R
    Br J Cancer; 2014 Sep; 111(6):1168-79. PubMed ID: 25093491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of sunitinib malate plus interferon-alpha for patients with metastatic renal cell carcinoma.
    Motzer RJ; Hudes G; Wilding G; Schwartz LH; Hariharan S; Kempin S; Fayyad R; Figlin RA
    Clin Genitourin Cancer; 2009 Jan; 7(1):28-33. PubMed ID: 19213665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC).
    Grünwald V; Desar IM; Haanen J; Fiedler W; Mouritzen U; Olsen MW; van Herpen CM
    Acta Oncol; 2011 Jan; 50(1):121-6. PubMed ID: 21174612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL; Small EJ; Weinberg VK; Sun J; Ryan CJ; Lin AM; Fong L; Brocks DR; Rosenberg JE
    Cancer; 2011 Sep; 117(18):4194-200. PubMed ID: 21387258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of lenalidomide in combination with sunitinib in patients with advanced or metastatic renal cell carcinoma.
    Rini B; Redman B; Garcia JA; Burris HA; Li S; Fandi A; Beck R; Jungnelius U; Infante JR
    Ann Oncol; 2014 Sep; 25(9):1794-1799. PubMed ID: 24914044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
    Amato RJ; Flaherty AL; Stepankiw M
    Clin Genitourin Cancer; 2012 Mar; 10(1):26-31. PubMed ID: 22169794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
    Campbell MT; Millikan RE; Altinmakas E; Xiao L; Wen SJ; Siefker-Radtke AO; Aparicio A; Corn PG; Tannir NM
    Clin Genitourin Cancer; 2015 Jun; 13(3):218-24. PubMed ID: 25465491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of sequential treatment with sunitinib-everolimus in an orthotopic mouse model of renal cell carcinoma.
    Larkin J; Esser N; Calvo E; Tsuchihashi Z; Fiedler U; Graeser R; Kim D
    Anticancer Res; 2012 Jul; 32(7):2399-406. PubMed ID: 22753696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on systemic therapies of metastatic renal cell carcinoma.
    Herrmann E; Bierer S; Wülfing C
    World J Urol; 2010 Jun; 28(3):303-9. PubMed ID: 20180125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.